Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter single-arm study of umbilical cord mesenchymal stem cells for acute-on-chronic (subacute) liver failure
CTR20212223Phase 2Active
- Sponsor
- Tianjin Angsai Cell Gene Engineering Co., Ltd.
- Start
- Feb 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic umbilical cord-derived mesenchymal stem cells (Tianjin Amcellgene Engineering) in acute-on-chronic liver failure (ACLF) (3 arms), sponsored by Tianjin Angsai Cell Gene Engineering Co., Ltd. Primary endpoints: Treatment-related adverse events, Dose-limiting toxicity and maximum tolerated dose and 1 more. Started Feb 2022; status: active.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells (Tianjin Amcellgene Engineering)
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on CTR20212223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212223.